Trials / Sponsors / Abdullah Khan
Abdullah Khan
Academic / Other · 2 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BC Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | 2023-12-21 |
| Terminated | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refra Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | 2021-09-27 |